Bioventix Share Discussion Threads

[melody9999] 13/8/2018 14:40

possibly just a bit of profit taking on the Turkish Delight uncertainty we are currently encountering in the main market!

[crazycoops] 13/8/2018 14:33

I'm guessing today's fall is a few people being spooked by FAB news - unrelated to BVXP of course but they have the word antibody in their name. Meanwhile BVXP is a net dollar earner, the dollar is strong and we have a trading update in a week or two. This will follow the 6-monthly royalty call with Siemens and should include updated guidance on troponin forecasts for FY19. One hopes this will lead the house broker to raise forecasts.

[amencorner] 26/7/2018 16:30

It's quite amazing that such an outstandingly high-quality stock is followed by so few and yet the "jam tomorrow" stuff gets a massive number of postings.

[robinnicolson] 18/7/2018 08:40

Note from finnCap:

Siemens Healthineers received 510(k) clearance from the FDA on 12 July for its high sensitivity troponin I test. The approval is significant for Bioventix as the test uses antibodies created by the company, for which it receives royalties based on sales of the test to Siemens’ customers. It is not clear currently when Siemens intends to launch this test. We are not changing forecasts for troponin, which are currently for £0.1m and £0.5m in FY 18 and FY 19, respectively. We expect the company to provide a trading update in late August when it has greater visibility of royalty payments. We will review forecasts then, at which point we should have greater clarity also over the US launch timetable. We are placing our target price under review until then.

[melody9999] 16/7/2018 17:27

Interesting Step - if one assumes that Troponin revenue at forecast levels is 'in the bag', then it would be disappointing if nothing else came to fruition in the 4 years until 2022.

So I guess your projections might be 'base case' with likelihood to the upside.

[stepone68] 16/7/2018 15:03

That 2022 forecast of 2.2m would put EPS around 135p (assuming flat performance from other product lines, but also assuming flat admin costs), so still on a PE in the mid 20s.

When I first bought this in Nov 2014 it was £7 with EPS of 45p, so the EPS has doubled but the price has quadrupled. How much higher can it go?

Cheers,
StepOne

[gsbmba99] 16/7/2018 14:37

finnCap troponin revenue forecast (covering Eur and US) as at Oct 17: £0.3m (18E); £0.7m (19E); £1.4m (20E); £1.8m (21E) and £2.2m (22E). Following 1H18 results, finnCap troponin estimate was amended to £0.1m (18E) and £0.5m (19E).

[stepone68] 16/7/2018 13:57

Yup, forecasts have been beaten every year recently, but it's not going to sit on a PE of 30 forever, so share price increases are going to be harder to come by, although fingers crossed that Finncap note turns out to be correct!

[carcosa] 16/7/2018 13:25

I recall a Finncapp note from 2015 saying Tropinin will 'dwarf' current business...

[crazycoops] 16/7/2018 13:03

If you believe the forecasts to be accurate!

[stepone68] 16/7/2018 12:45

Agreed, but it does now sit on 32 times forecasts, so not exactly cheap.

[steptoes yard] 16/7/2018 12:05

Topped up. Be rude not to. Almost operates at fixed cost and has an expanding royalty stream.

[igbertsponk] 16/7/2018 11:40

Indeed. What a super well-run company this is.

[nfs] 16/7/2018 11:34

Thanks Leon, explains the nice bump today

[boros10] 16/7/2018 10:40

Siemens appear to have gained FDA approval for its high sensitivity Troponin I (TNIH) assay on its ADVIA Centaur blood machine. This assay contains Bioventix's monoclonal sheep antibody and it should mean a significant increase in earnings once fully embedded across Siemen's estate of blood machines. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K171274

[igbertsponk] 10/7/2018 08:48

Ta - looks a good website and good prospects.

[gsbmba99] 10/7/2018 08:44

Cardinor, in which BVXP has an equity stake and with whom they are collaborating on the experimental biomarker secretoneurin, finally has a website up and running. cardinor.com An affiliated researcher will be presenting at the European Society of Cardiology gathering in Munich in August on "Low concentrations of circulating secretoneurin predict a favorable prognosis after cardiac surgery". Sounds interesting. Beckman Coulter received FDA 510(k) clearance for their hs Troponin test a couple of weeks ago.

[scillyfool] 05/7/2018 14:08

Up another 3%+ today and heading for £31. Still awaiting news on the Siemens tie-up. With a staff of only 13 any new business falls straight to the bottom line and into the special dividend pot, as they have no need for a large amount of working capital, according to their report. P/E of 28 looks okay to me.

[igbertsponk] 04/7/2018 15:02

Popped through £30 again, hope will establish this as a new level.

[valustar1] 20/6/2018 17:21

Trade today 4K at. £30.10

[tadders2] 17/6/2018 08:14

Agree Lauders....a brief write up from anybody who was there would be very welcome.

[lauders] 17/6/2018 04:22

Anyone heard or seen anything in writing about the recent Mello presentation? Been very quiet unless I missed some reports somewhere.

[igbertsponk] 14/6/2018 10:58

All those trades - 200 shares so far!

[robinnicolson] 14/6/2018 10:35

Post Mello buying? The presentation was scheduled to finish at 10 this morning.